Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

@article{Bent2003SecondlineCW,
  title={Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.},
  author={Martin J. van den Bent and Olivier L. Chinot and Willem Boogerd and Jos{\'e} Bravo Marques and Martin J. B. Taphoorn and Johannes M Kros and Carin C. D. van der Rijt and Charles J. Vecht and N De Beule and Beno{\^i}t Baron},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2003},
  volume={14 4},
  pages={599-602}
}
BACKGROUND Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine. Temozolomide (TMZ), a new alkylating and methylating agent has shown high response rates in recurrent anaplastic astrocytoma. We investigated this drug in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after prior PCV chemotherapy and radiation therapy. PATIENTS AND METHODS In a prospective… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.

Neuropathology : official journal of the Japanese Society of Neuropathology • 2018

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2001
View 1 Excerpt

Resistance of anaplastic oligodendroglioma (AO) to procarbazine–CCNU–vincristine (PCV) is correlated to a glioblastoma

O Chinot, M Barrie, H Dufour
Proc Am Soc Clin Oncol • 2001
View 1 Excerpt

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy

O Chinot, S Honore, M Barrie
J Clin Oncol • 2001
View 3 Excerpts

Salvage chemotherapy with carboplatin for recurrent oligodendroglial tumors

M Nobile, A Costanza, R Rudà
Neuro-Oncology • 2001
View 1 Excerpt

Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.

Annals of oncology : official journal of the European Society for Medical Oncology • 2001
View 1 Excerpt

Similar Papers

Loading similar papers…